Lysine-specific demethylase 7A (KDM7A): A potential target for disease therapy

Chang-Yun Li,Yan-Jun Liu,Fan Tao,Ru-Yi Chen,Jin-Jin Shi,Jian-Fei Lu,Guan-Jun Yang,Jiong Chen,Guan–Jun Yang
DOI: https://doi.org/10.1016/j.bcp.2023.115799
IF: 6.1
2023-09-11
Biochemical Pharmacology
Abstract:Histone demethylation is a kind of epigenetic modification mediated by a variety of enzymes and participates in regulating multiple physiological and pathological events. Lysine-specific demethylase 7A is a kind of α-ketoglutarate- and Fe(II)-dependent demethylase belonging to the PHF2/8 subfamily of the JmjC demethylases. KDM7A is mainly localized in the nucleus and contributes to transcriptional activation via removing mono- and di-methyl groups from the lysine residues 9 and 27 of Histone H3. Mounting studies support that KDM7A is not only necessary for normal embryonic, neural, and skeletal development, and but also associated with cancer, inflammation, osteoporosis, and other diseases. Herein, the structure of KDM7A is described by comparing the similarities and differences of its amino acid sequences of KDM7A and other Histone demethylases; the functions of KDM7A in homeostasis and dyshomeostasis are summarized via documenting its content and related signaling; the currently known KDM7A-specific inhibitors and their structural relationship are listed based on their structure optimization and pharmacological activities; and the challenges and opportunities in exploring functions and developing targeted agents of KDM7A are also prospected via presenting encountered problems and potential solutions, which will provide an insight in functional exploration and drug discovery for KDM7A-related diseases.
pharmacology & pharmacy
What problem does this paper attempt to address?